Pharma and biotech M&A activity

Statistics report about M&A deals in the pharma and biotech industry

Pharma and biotech M&A activity

This report presents key facts and figures about mergers and acquisitions in the pharmaceutical and biotech industry worldwide. For biopharmaceutical companies, M&A deals are often essential for generating growth and acquiring knowledge. This report provides a good introduction into the M&A landscape of the industry, including volume, value, and type of deals, as well as an outlook on what trends are expected for 2021.

Table of contents

Industry overview

5
  • Premium Statistic Pharmaceutical market: worldwide revenue 2001-2023
  • Premium Statistic Global biotech drug sales estimate 2012-2023
  • Premium Statistic Top 10 biotech and pharmaceutical companies based on market cap 2024
  • Premium Statistic Top 50 pharmaceutical companies - Rx sales and R&D spending 2022
  • Premium Statistic Top pharmaceutical companies by capex growth in 2022

Number of deals

7
  • Premium Statistic Planned and actual healthcare and life sciences activity in 2020, by subsector
  • Basic Statistic Global number of life sciences sector deals 2013-2021
  • Premium Statistic Number of biopharmaceutical deals worldwide 2016-2020, by type
  • Basic Statistic Number of cell and gene therapy deals worldwide 2016-2020, by type
  • Premium Statistic Number of biopharma M&A deals worldwide 2010-2019, by companies
  • Basic Statistic Number of biopharma M&A deals worldwide 2010-2019, by total transaction value
  • Premium Statistic Number of biopharma M&A deals worldwide 2010-2019, by industry

Value of deals

5
  • Premium Statistic Largest M&A pharmaceutical deals ever as of 2024
  • Basic Statistic Global value of life sciences sector deals 2013-2021
  • Basic Statistic Top completed life sciences deals based on value globally 2020
  • Premium Statistic Value of biopharma M&A deals worldwide 2010-2019, by industry
  • Premium Statistic Average value of biopharma M&A deals worldwide 2010-2019, by industry

Mega-merger: BMS/Celgene

5
  • Premium Statistic Bristol-Myers Squibb's revenue 2006-2023
  • Basic Statistic Bristol-Myers Squibb revenue by segment 2015-2020
  • Basic Statistic Celgene's revenue and net income 2006-2018
  • Premium Statistic Revenue of Celgene 2016-2018, by therapeutic area
  • Premium Statistic Top pharma companies worldwide 2023, by size of R&D pipeline

2021 outlook

4
  • Basic Statistic Expected acquisitions of biopharma companies by type of asset 2021
  • Basic Statistic Expected investment in biopharma and diagnostic lab services 2021, by type
  • Basic Statistic Expected valuation changes in healthcare and life sciences 2021, by subsector
  • Premium Statistic Expected investment changes in biopharma and diagnostic lab services 2021

Statista report shop

Explore all Statista reports

We provide information on industries, companies, consumers, trends, countries, and politics, covering the latest and most important issues in a condensed format.

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Kisara Mizuno
Kisara Mizuno
Senior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)